HEAD &amp; NECK CANCERS

Pegylation Chemistry of NKTR-214 in Melanoma

Pathophysiology of the Tumor Microenvironment in Melanoma

The PIVOT-02 Trial: NKTR-214 With Nivolumab

Synergistic Activity of NKTR-214 With Nivolumab

Latest Videos

Locally Advanced NSCLC: Durvalumab and the PACIFIC Trial

Unmet Needs and Role of Immunotherapy in Stage 3 NSCLC

Chemotherapy Approaches in Locally Advanced NSCLC

Locally Advanced NSCLC: Workup and Treatment Approach

Immunotherapy in Unresectable Locally Advanced NSCLC

Future Role of Immunotherapy in NSCLC

Dual Checkpoint Inhibition in NSCLC

NSCLC: Practical Considerations With Quadruplet Regimen

Quadruplet Therapy in NSCLC: IMpower150

NSCLC: Immunotherapy Toxicity Management

CME Content

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Webinar Series

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Neil M. Iyengar, MD; Ajit K. Bisen, MD, MBA

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Erika P. Hamilton, MD; Katherine Sanchez, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Iowa Oncology Society

Wassim Mchayleh, MD, MBA, FACP; Trevor Feinstein, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Louisiana Oncology Society

Virginia Kaklamani, MD, DSc

Oncology Town Hall: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Webinar Series

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; Banu Arun, MD, FASCO

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Multimedia

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH